DEPALEPT SYRUP Israël - Engels - Ministry of Health

depalept syrup

cts chemical industries ltd, israel - valproic acid as sodium - syrup - valproic acid as sodium 40 mg/ml ml - valproic acid - valproic acid - generalized or partial epilepsy secondary generalized epilepsy and mixed forms of epilepsy.

DEPALEPT 200 MG Israël - Engels - Ministry of Health

depalept 200 mg

cts chemical industries ltd, israel - valproic acid as sodium - tablets enteric coated - valproic acid as sodium 200 mg - valproic acid - valproic acid - anti-epileptic.

DEPALEPT ORAL SOLUTION Israël - Engels - Ministry of Health

depalept oral solution

cts chemical industries ltd, israel - valproic acid as sodium - solution (oral) - valproic acid as sodium 200 mg/ml - valproic acid - treatment of generalized or partial epilepsy secondary generalized epilepsy and mixed forms of epilepsy.

VALPRO EC500 sodium valproate 500 mg enteric coated tablet blister pack Australië - Engels - Department of Health (Therapeutic Goods Administration)

valpro ec500 sodium valproate 500 mg enteric coated tablet blister pack

sanofi-aventis australia pty ltd - sodium valproate, quantity: 500 mg - tablet, enteric coated - excipient ingredients: citric acid monohydrate; hypromellose; polyvinyl acetate phthalate; diethyl phthalate; purified talc; hyprolose; titanium dioxide; povidone; magnesium stearate; amaranth aluminium lake; calcium silicate; indigo carmine aluminium lake; stearic acid; macrogol 6000 - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

VALPRO EC200 sodium valproate 200 mg enteric coated tablet blister pack Australië - Engels - Department of Health (Therapeutic Goods Administration)

valpro ec200 sodium valproate 200 mg enteric coated tablet blister pack

sanofi-aventis australia pty ltd - sodium valproate, quantity: 200 mg - tablet, enteric coated - excipient ingredients: hypromellose; stearic acid; indigo carmine aluminium lake; purified talc; calcium silicate; citric acid monohydrate; amaranth aluminium lake; macrogol 6000; povidone; hyprolose; titanium dioxide; diethyl phthalate; polyvinyl acetate phthalate; magnesium stearate - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

VALWOK sodium valproate 1000 mg/10 mL solution for injection ampoule Australië - Engels - Department of Health (Therapeutic Goods Administration)

valwok sodium valproate 1000 mg/10 ml solution for injection ampoule

wockhardt bio pty ltd - sodium valproate, quantity: 1000 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - valwok is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

VALWOK sodium valproate 400 mg/4 mL solution for injection ampoule Australië - Engels - Department of Health (Therapeutic Goods Administration)

valwok sodium valproate 400 mg/4 ml solution for injection ampoule

wockhardt bio pty ltd - sodium valproate, quantity: 400 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - valwok is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

SODIUM VALPROATE WOCKHARDT sodium valproate 1000 mg/10 mL solution for injection ampoule Australië - Engels - Department of Health (Therapeutic Goods Administration)

sodium valproate wockhardt sodium valproate 1000 mg/10 ml solution for injection ampoule

wockhardt bio pty ltd - sodium valproate, quantity: 1000 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

SODIUM VALPROATE WOCKHARDT sodium valproate 400 mg/4 mL solution for injection ampoule Australië - Engels - Department of Health (Therapeutic Goods Administration)

sodium valproate wockhardt sodium valproate 400 mg/4 ml solution for injection ampoule

wockhardt bio pty ltd - sodium valproate, quantity: 400 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

BOSENTAN APO bosentan (as monohydrate) 62.5 mg film-coated tablet bottle Australië - Engels - Department of Health (Therapeutic Goods Administration)

bosentan apo bosentan (as monohydrate) 62.5 mg film-coated tablet bottle

arrotex pharmaceuticals pty ltd - bosentan monohydrate, quantity: 64.541 mg - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate type a; glycerol dibehenate; povidone; maize starch; pregelatinised maize starch; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; ethylcellulose - bosentan is indicated for the treatment of,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with scleroderma or,? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms